Claim 20% Off With Code ONLINE20 – Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights
What Is the Potential Market Growth Rate of the Nocturnal Enuresis Medication Market?
The nocturnal enuresis medication market size has grown strongly in recent years. It will grow from $1.53 billion in 2024 to $1.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to high global prevalence of nocturnal enuresis among children, increasing recognition of adult nocturnal enuresis, growing pediatric population worldwide, higher diagnosis rates due to improved screening protocols, and increasing incidence of comorbid conditions.
The nocturnal enuresis medication market size is expected to see strong growth in the next few years. It will grow to $2.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to rise in stress-related bladder dysfunction in children, an increase in secondary enuresis cases post psychological trauma, government programs promoting child healthcare, expansion of telemedicine for remote diagnosis and treatment, and the emergence of e-pharmacies improving drug access. Major trends in the forecast period include advancements in drug formulations, development of new delivery mechanisms, approval of novel therapeutic agents, combination therapies gaining traction, and shorter drug development timelines using AI and precision medicine.
Claim your free report sample now:
Who Are the Major Contributors to the Nocturnal Enuresis Medication Market Growth?
The increasing demand for personalized care is expected to fuel the growth of the nocturnal enuresis medication market going forward. Personalized care refers to a medical approach that tailors treatment and healthcare strategies to an individual's unique genetic profile, lifestyle, preferences, and specific health conditions, ensuring more targeted and effective outcomes. The growing demand for personalized care is due to advancements in medical technology that allow healthcare providers to tailor treatments based on each patient’s genetics, lifestyle, and health conditions, leading to more effective and targeted care. Personalized care supports nocturnal enuresis medication by tailoring treatment plans to an individual's specific medical history, lifestyle, and underlying causes, thereby improving the effectiveness and adherence to the therapy. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the Food and Drug Administration (FDA), a US-based federal agency, approved 16 new personalized treatments in 2023 for rare disease patients, up from 6 in 2022. Therefore, increasing demand for personalized care is driving the growth of the nocturnal enuresis medication market.
What Are the Key Segments in the Nocturnal Enuresis Medication Market?
The nocturnal enuresis medication market covered in this report is segmented –
1) By Drug Class: Desmopressin, Imipramine, Oxybutynin, Combined Pharmacotherapy, Antidepressants
2) By Age Group: Children, Adolescents, Adults, Elderly
3) By Formulation Type: Tablets, Liquid Solutions, Sprays, Patches, Extended-Release Formulations
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Desmopressin: Oral Tablets, Nasal Sprays, Sublingual Tablets
2) By Imipramine: Oral Tablets, Extended-Release Capsules
3) By Oxybutynin: Immediate-Release Tablets, Extended-Release Tablets, Transdermal Patches, Syrups
4) By Combined Pharmacotherapy: Desmopressin And Oxybutynin, Desmopressin And Imipramine, Oxybutynin And Imipramine
5) By Antidepressants: Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Which Emerging Trends Are Driving the Nocturnal Enuresis Medication Market?
Major companies operating in the nocturnal enuresis medication market are focusing on developing advanced solutions, such as orally disintegrating tablets (ODT), to offer ease of administration. Orally disintegrating tablets (ODTs) are solid dosage forms that dissolve or disintegrate quickly in the mouth without the need for water, making them ideal for patients with swallowing difficulties. For instance, in March 2024, Adalvo Limited, a Malta-based pharmaceutical company, launched desmopressin orally disintegrating tablets (ODT) in Europe. Desmopressin ODT is specifically designed for the treatment of primary nocturnal enuresis, offering a convenient and easy-to-administer option that rapidly disintegrates in the mouth. This unique formulation is particularly beneficial for pediatric and elderly patients, as well as those with difficulty swallowing tablets. The launch highlights Adalvo’s dedication to providing high-quality, differentiated pharmaceutical products while improving patient access to vital therapies through strategic industry partnerships.
Who Are the Prominent Players in theNocturnal Enuresis Medication Market?
Major companies operating in the nocturnal enuresis medication market are Pfizer Inc., Merck & Co. Inc., Dr. Willmar Schwabe GmbH & Co. KG, Ferring Pharmaceuticals A/S, UroGen Pharma Ltd., Bakson Drugs and Pharmaceuticals Pvt. Ltd., Nordic Pharma Group, Dr. Reckeweg & Co. GmbH, Chummie, Taiho Pharmaceutical Co. Ltd., AA Pharma Inc., Bakson Drugs and Pharmaceuticals Pvt. Ltd., Aark Pharmaceuticals Ltd., Alturix Ltd., Wellesley Pharmaceuticals LLC, German Homoeo Care and Cure Pvt. Ltd., Laboratoires Ledoux Reflexe Inc., Global Continence Inc., Serenity Pharmaceuticals LLC, Vantia Therapeutics Ltd.
Get the full nocturnal enuresis medication market report here:
Which Regions Are Forecasted to Experience the Fastest Growth in the Nocturnal Enuresis Medication Market?
North America was the largest region in the nocturnal enuresis medication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nocturnal enuresis medication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment